VYNE News and Press, VYNE Therapeutics Inc Com From 03/15/21

The following slide deck was published by VYNE Therapeutics Inc. in conjunction with this event. For further details see: VYNE Therapeutics (VYNE) Investor Presentation - Slideshow

Evofem Biosciences EVFM -25% on Q4 earnings release.Super League Gaming (SLGG) -19%.GSX Techedu GSX -15% on Q4 earnings release.T2 Biosystems TTOO -10% on Q4 earnings release.Senseonics Holdings SENS -9% on Q4 earnings release.Aerpio Pharmaceuticals ARP...

Foamix Pharmaceuticals Ltd (FOMX) Q4 2020 Earnings Conference Call March 4, 2021 08:30 ET Company Participants Michael Wood - Investor Relations Dave Domzalski - President and Chief Executive Officer Matt Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Iain Stuart - Chi...

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C....

Image source: The Motley Fool. VYNE Therapeutics Inc. (NASDAQ: VYNE) Q4 2020 Earnings Call Mar 04, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: VYNE Therapeutics Inc. (VYNE) Q4 2020 Earnings Call Transcript

VYNE Therapeutics (VYNE): Q4 Non-GAAP EPS of -$0.43 beats by $0.08; GAAP EPS of -$0.55 misses by $0.09.Revenue of $4.29M (+2964.3% Y/Y) misses by $0.69M.Shares -2.7% PM.Press Release For further details see: VYNE Therapeutics EPS beats by $0.08, misses on revenue

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. “We conti...

BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41 st Annual Health Care Conference....

VYNE Therapeutics (VYNE) perks 5% premarket after announcing its development plans for FMX114 for the potential treatment of mild-to-moderate atopic dermatitis ((AD)).Phase 2a clinical trial evaluating FMX114 is expected to begin in Q3 with top-line results anticipated by year end. ...

Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including clinical development plans, will be discussed on VYNE’s year end 2020 earnings call at 8:30am ET ...